A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients
Flume, Patrick; VanDevanter, Donald R.; Morgan, E.E.; Dudley, Michael N.; Loutit, Jeffery S.; Bell, Scott C.; Kerem, Eitan; Fischer, R.; Smyth, Alan R.; Aaron, Shawn D.; Conrad, Douglas; Geller, David E.; Elborn, J. Stuart
Donald R. VanDevanter
Michael N. Dudley
Jeffery S. Loutit
Scott C. Bell
ALAN SMYTH firstname.lastname@example.org
Professor of Child Health
Shawn D. Aaron
David E. Geller
J. Stuart Elborn
For patients with cystic fibrosis (CF), the use of inhaled antibiotics has become standard of care to suppress chronic Pseudomonas airways infection. There are limited antibiotic options formulated and approved for inhaled use and antibiotic efficacies attenuate over time, making additional inhaled antibiotic classes desirable. APT-1026 (levofloxacin inhalation solution, LIS) is a fluoroquinolone in development for management of chronic P. aeruginosa airways infection in patients with CF.
To compare the safety and efficacy of a 28-day course of treatment with LIS 240 mg or placebo BID in persons ≥ 12 years old with CF and chronic P. aeruginosa infection.
A multinational, randomized (2:1), double-blinded study of LIS and placebo over 28 days in CF patients ≥ 12 years with chronic P. aeruginosa infection. Time to exacerbation was the primary endpoint. FEV1 (% predicted) and patient-reported quality of life were among secondary endpoints.
Baseline demographics for 330 subjects (LIS = 220) were similar although significantly more patients randomized to LIS had experienced multiple exacerbations in the year prior to study entry. There was no statistically significant difference in protocol-defined pulmonary exacerbations between treatment arms. Relative change in FEV1% predicted from baseline was significantly greater for patients randomized to LIS compared to those randomized to placebo (mean difference 1.31%, p = 0.01 [95% CI 0.27, 2.34%]). LIS was well-tolerated, with dysguesia the most frequent adverse event.
LIS did not demonstrate a difference in time to next exacerbation when compared to placebo. Reasons for this result are discussed but may be due to an imbalance in the frequency of prior pulmonary exacerbations between the two groups. An improvement in FEV1 (% predicted) at 28 days was observed and LIS was well tolerated. LIS is safe and has a potential role in the management of CF patients with chronic P. aeruginosa.
Flume, P., VanDevanter, D. R., Morgan, E., Dudley, M. N., Loutit, J. S., Bell, S. C., …Elborn, J. S. (2016). A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 15, doi:10.1016/j.jcf.2015.12.004
|Journal Article Type||Article|
|Acceptance Date||Dec 2, 2015|
|Online Publication Date||Feb 4, 2016|
|Publication Date||Jul 1, 2016|
|Deposit Date||Oct 19, 2016|
|Publicly Available Date||Oct 19, 2016|
|Journal||Journal of Cystic Fibrosis|
|Peer Reviewed||Peer Reviewed|
|Keywords||Cystic fibrosis; Antibiotics; Pseudomonas; Aerosol; Fluoroquinolone|
|Copyright Statement||Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0|
Flume_LIS_revision_ trackchanges AS 051015.pdf
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0
You might also like
Preprint servers: a ‘rush to publish’ or ‘just in time delivery’ for science?